Cafeity Get the app

Side effects

Hair loss on a GLP-1 medicine

Finding more hair than usual in the brush a few months in is upsetting, and it is one of the side effects people are least prepared for. The labels record it, link it to weight reduction rather than to the medicine as such, and show it is reported far more by women than by men.

By the Cafeity teamUpdated 4 min read

The short answer

Hair loss is a listed side effect on the weight-management labels: 3.3% on semaglutide 2.4 mg against 1% on placebo, 4–5% on tirzepatide against 1%, and 4–5% on orforglipron against 2%.123 The labels say it was associated with weight reduction, and it was reported mainly by women — 7.1% of women against 0.5% of men on tirzepatide.2 Shedding after rapid weight loss is usually a temporary form called telogen effluvium, which typically improves over months.4 Protein and nutrients matter; patchy loss, scalp symptoms or shedding beyond six months are worth a doctor's look.

Bar chart of hair loss by sex: women on semaglutide 2.4 mg 4% versus 2% on placebo; women on tirzepatide 7.1% versus 1.3%; women on orforglipron 7% versus 3%; men on any of the three at most 0.9% versus 0.7% on placebo.
Hair loss reported by women and men in the weight-management trials, from each label. Men's bar shows the highest figure reported for men across the three labels.

How common it is

Hair loss in placebo-controlled trials, from the current US prescribing information for each medicine. Rates from different medicines' trials are not directly comparable.
Medicine (trial population)PlaceboMedicine
Semaglutide 2.4 mg weekly injection (adults with obesity or overweight)1%3%
Semaglutide 7.2 mg weekly injection (adults with obesity)1%3% (2.4 mg), 6% (7.2 mg)
Tirzepatide weekly injection (adults with obesity or overweight)1%5% (5 mg), 4% (10 mg), 5% (15 mg)
Orforglipron daily tablet (adults with obesity or overweight)2%4% (5.5 mg), 4% (9 mg), 5% (17.2 mg)
Hair loss by sex, as reported in the label text.
MedicineWomenMen
Semaglutide 2.4 mg (placebo)4% (2%)0.9% (0%)
Semaglutide 7.2 mg (placebo)8.4% (1.5%)0.2% (0%)
Tirzepatide (placebo)7.1% (1.3%)0.5% (0%)
Orforglipron (placebo)7% (3%)0.9% (0.7%)

Sources: prescribing information.123

Very few people stopped treatment because of it: no one on tirzepatide in its weight-management trials, against one person on placebo.2

Why it happens

Each label says the same thing: hair loss adverse reactions were associated with weight reduction.123 That fits a well-known pattern. A shock to the body — rapid weight loss, illness, surgery, childbirth — can push many hair follicles into their resting phase at once, and a few months later they shed together. It is called telogen effluvium, and it is usually temporary.4

Why women report it far more is not explained in the labels. The figures are given separately for women and men, so the difference is not simply because most trial participants were women.

Does it grow back?

Telogen effluvium typically starts two to three months after the trigger, usually lasts three to six months, and is followed by regrowth; rapid weight loss and diets short on protein are among the recognised triggers.4 The labels do not report long-term follow-up of hair specifically. If loss is patchy, comes with scalp itching or scaling, or continues beyond about six months, see a doctor — other causes, including thyroid problems and iron deficiency, are worth ruling out.

What tends to help

The 2025 joint advisory for people on these medicines stresses adequate protein and preventing micronutrient deficiencies — shortfalls become more likely when intake falls a long way.5 Gentle hair care (less heat and tight styling) is sensible while shedding lasts. Supplements marketed for hair are best discussed with a pharmacist or doctor, particularly before taking high doses of anything.

When to contact your prescriber

Keeping a record of it

Rapid weight change is the clue the labels point to, so the useful record puts the two side by side: your smoothed weight trend and when the shedding started. Cafeity keeps both, with notes you can tag for your prescriber.

Cafeity weight screen showing a smoothed trend weight of 115.6 kg, down 5.5 kg since last week, with the note "Based on your recent rate. Not a prediction."
The rate of change, as a smoothed trend.
Cafeity "Your week, understood" screen: Ora explains that everything is calculated from your own log, offers questions such as "When are my symptoms worst?", and shows the week's protein, energy, water, weight trend, symptom days and a note that protein was 80 g under target.
Notes and patterns from your own log.

Download Cafeity on the App Store

Common questions

Does GLP-1 hair loss grow back?
Shedding after rapid weight loss is usually telogen effluvium, which typically lasts three to six months and is followed by regrowth.4 Persistent or patchy loss should be checked by a doctor.
Why do women lose more hair on GLP-1 medicines?
The labels report it far more in women — for example 7.1% against 0.5% on tirzepatide — without giving a reason.2
Is hair loss caused by the medicine or the weight loss?
The labels associate it with weight reduction.12

Sources

  1. Semaglutide injection and tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 30 June 2026
  2. Tirzepatide injection for weight management and obstructive sleep apnoea — US prescribing information DailyMed, US National Library of Medicine, version published 2 September 2026
  3. Orforglipron tablets for weight management — US prescribing information DailyMed, US National Library of Medicine, version published 13 August 2026
  4. Telogen effluvium: symptoms, causes, treatment and regrowth Cleveland Clinic
  5. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society Mozaffarian D et al. 2025 (published in four journals)

Written by the Cafeity team from the sources listed here. Figures from prescribing information are quoted as the label states them; trial results are averages from those trials, not predictions for any one person. This page has not yet been reviewed by a clinician — see the editorial policy for how pages are researched and corrected.